You just read:

Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma

News provided by

Novartis Pharmaceuticals Corporation

Jun 06, 2016, 14:40 ET